RNA-Micelles as Self-Assembling Structures for Efficient Co-Delivery of Synergistic siRNA and Nucleoside Analogues to
Kai Jin1, Piotr Rychahou2, Daniel W Binzel1
1Division of Pharmaceutics and Pharmacology, College of Pharmacy, Center for RNA Nanobiotechnology and Nanomedicine, Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Abstract:
SiRNA has been widely studied in cancer gene silencing over the last 25 years. However, few siRNA-based therapeutics have been approved by the FDA. An RNA-micelle platform provides a powerful therapeutic tool through simple one-step, high-yield production that is capable of efficient colorectal cancer lung metastasis treatment, a current lethal condition with a short survival rate post-diagnosis. Here, it is reported that the use of RNA-micelles co-carrying siRNA and nucleoside analogues to completely inhibit lung metastasis of colorectal cancer (CRC). The major advantage of the RNA-micelle is the successful co-delivery of siRNA and chemotherapeutic agent in a single delivery vehicle while specifically targeting CRC cells via incorporation of an oncogenic surface receptor ligand. It was found that RNA-micelles could combine to silence survivin protein expression via siRNA delivery, which in turn increased the efficacy of the delivered chemotherapeutic agent. Both siRNA and high-payload nucleoside-analogues were incorporated onto a single micelle, which remained stable during in vivo circulation, rather than individual RNA nanoparticles, thus generating this advantageous synergistic cancer regression. This platform provides a powerful therapeutic tool to address colorectal cancer lung metastasis, a currently serious, lethal disease that has a very poor prognosis following diagnosis.
Insights
This study introduces an RNA-micelle platform for treating colorectal cancer lung metastasis. The novel system effectively co-delivers siRNA and chemotherapy, significantly inhibiting cancer spread and improving therapeutic outcomes.
Area of Science:
- Biotechnology
- Oncology
- Nanomedicine
Background:
- Small interfering RNA (siRNA) has shown promise for cancer gene silencing but faces challenges in therapeutic development.
- Colorectal cancer (CRC) lung metastasis is a lethal condition with a poor prognosis and limited treatment options.
Purpose of the Study:
- To develop and evaluate an RNA-micelle platform for the co-delivery of siRNA and nucleoside analogues.
- To assess the efficacy of this platform in inhibiting colorectal cancer lung metastasis.
Main Methods:
- An RNA-micelle platform was engineered for high-yield, one-step production.
- The platform co-delivered siRNA targeting survivin and nucleoside analogues specifically to CRC cells via surface receptor ligands.
- In vivo stability and therapeutic efficacy were evaluated.
Main Results:
- The RNA-micelle platform successfully co-delivered siRNA and chemotherapeutics in a single vehicle.
- Co-delivery resulted in synergistic cancer regression by silencing survivin and enhancing chemotherapy efficacy.
- The platform demonstrated stability during in vivo circulation and effectively inhibited lung metastasis.
Conclusions:
- The RNA-micelle platform offers a powerful therapeutic tool for colorectal cancer lung metastasis.
- This approach overcomes limitations of individual siRNA delivery and provides a synergistic treatment strategy.
- The platform holds potential for addressing this lethal condition with a poor prognosis.
Related Concept Videos
01:22MicroRNAs
02:15Experimental RNAi